Log in to your Inderes Free account to see all free content on this page.
Oncopeptides
1.52
SEK
+1.2 %
ONCO
NASDAQ Stockholm
Biotechnology & Pharmaceuticals
Health Care
2 following
+1.2%
-29.79%
-30.91%
-43.81%
-72.16%
-75.26%
-74.46%
-98.33%
-95.04%
www.oncopeptides.com/en/investors
Oncopeptides is a biotech company that develops drugs for difficult-to-treat hematological diseases. The company uses its PDC platform to develop peptide-linked drugs that selectively deliver cytotoxic drugs into cancer cells. The company has drugs in commercialization and several drug candidates under development. Oncopeptide's head office is located in Stockholm.
Revenue
35.22M
EBIT %
-719.62 %
P/E
-
Dividend yield-%
-
Target price
-
Recommendation
-
Updated
-
NASDAQ Stockholm
ONCO
Daily low / high price
1.49 / 1.52
SEK
Market cap
327.08M SEK
Turnover
43.69K SEK
Volume
29K
Latest videos
Financial calendar
Annual report
27.02.2025
Interim report
08.05.2025
General meeting
22.05.2025
Interim report
21.08.2025
Interim report
05.11.2025
Major OwnersSource: Millistream Market Data AB
Owner | Capital | Votes |
---|---|---|
HealthCap VIII L.P. | 12.7 % | 12.9 % |
HealthCap VI L.P. | 6.6 % | 6.7 % |
Premium
This content is for our Premium customers only.
ShowingAll content types
Oncopeptides invited to present data on PDC platform efficacy in Acute Myeloid Leukemia at the American Society of Hematology meeting
Redeye: Oncopeptides Q3 2024 - Sluggish Growth
Join Inderes community
Don't miss out - create an account and get all the possible benefits
FREE account
Stock market's most popular morning newsletter
Analyst comments and recommendations
Stock comparison tool
PREMIUM account
All company reports and content
Premium tools (e.g. insider transactions & stock screener)
Model portfolio